Impax Asset Management Group plc Has $495,000 Stock Position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Impax Asset Management Group plc reduced its holdings in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNYFree Report) by 10.9% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 2,587 shares of the biopharmaceutical company’s stock after selling 316 shares during the quarter. Impax Asset Management Group plc’s holdings in Alnylam Pharmaceuticals were worth $495,000 at the end of the most recent reporting period.

Other hedge funds have also recently made changes to their positions in the company. Quent Capital LLC grew its holdings in shares of Alnylam Pharmaceuticals by 246.0% during the fourth quarter. Quent Capital LLC now owns 173 shares of the biopharmaceutical company’s stock valued at $33,000 after buying an additional 123 shares during the last quarter. KB Financial Partners LLC bought a new position in shares of Alnylam Pharmaceuticals during the first quarter valued at about $35,000. Anchor Investment Management LLC bought a new position in shares of Alnylam Pharmaceuticals during the fourth quarter valued at about $38,000. Northwestern Mutual Wealth Management Co. lifted its position in shares of Alnylam Pharmaceuticals by 59.4% during the fourth quarter. Northwestern Mutual Wealth Management Co. now owns 373 shares of the biopharmaceutical company’s stock valued at $89,000 after purchasing an additional 139 shares in the last quarter. Finally, First Capital Advisors Group LLC. bought a new position in shares of Alnylam Pharmaceuticals during the second quarter valued at about $80,000. 92.97% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of research firms recently weighed in on ALNY. Wolfe Research began coverage on shares of Alnylam Pharmaceuticals in a research report on Thursday, February 15th. They set a “peer perform” rating on the stock. Wells Fargo & Company dropped their price target on shares of Alnylam Pharmaceuticals from $171.00 to $161.00 and set an “equal weight” rating on the stock in a research report on Friday, February 16th. Citigroup dropped their price target on shares of Alnylam Pharmaceuticals from $237.00 to $227.00 and set a “buy” rating on the stock in a research report on Friday, February 16th. JPMorgan Chase & Co. raised their price target on shares of Alnylam Pharmaceuticals from $150.00 to $170.00 and gave the company a “neutral” rating in a research report on Thursday, February 1st. Finally, The Goldman Sachs Group lowered shares of Alnylam Pharmaceuticals from a “buy” rating to a “neutral” rating and lowered their price objective for the stock from $230.00 to $173.00 in a research report on Friday, February 16th. Nine equities research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the stock. According to data from MarketBeat.com, Alnylam Pharmaceuticals currently has an average rating of “Moderate Buy” and a consensus target price of $216.12.

Read Our Latest Research Report on ALNY

Alnylam Pharmaceuticals Stock Down 0.2 %

NASDAQ ALNY opened at $152.09 on Friday. The company’s 50 day moving average is $154.48 and its 200-day moving average is $168.00. Alnylam Pharmaceuticals, Inc. has a 12-month low of $143.52 and a 12-month high of $218.88. The firm has a market cap of $19.16 billion, a P/E ratio of -42.72 and a beta of 0.39.

Alnylam Pharmaceuticals (NASDAQ:ALNYGet Free Report) last posted its quarterly earnings results on Thursday, February 15th. The biopharmaceutical company reported ($1.10) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.20) by $0.10. The business had revenue of $439.72 million during the quarter, compared to the consensus estimate of $439.38 million. During the same period last year, the firm earned ($1.68) EPS. The business’s revenue for the quarter was up 31.2% on a year-over-year basis. Equities analysts expect that Alnylam Pharmaceuticals, Inc. will post -4.61 EPS for the current year.

Alnylam Pharmaceuticals Profile

(Free Report)

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.

Featured Articles

Want to see what other hedge funds are holding ALNY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNYFree Report).

Institutional Ownership by Quarter for Alnylam Pharmaceuticals (NASDAQ:ALNY)

Receive News & Ratings for Alnylam Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.